As of 11:17am ET
| -0.05 / -1.49%|
The 7 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 5.00, with a high estimate of 10.00 and a low estimate of 2.00. The median estimate represents a +51.52% increase from the last price of 3.30.
The current consensus among 10 polled investment analysts is to Hold stock in BioCryst Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.